{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:20:38Z","timestamp":1762096838404,"version":"build-2065373602"},"reference-count":181,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bcp.2023.115989","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T19:30:22Z","timestamp":1702927822000},"page":"115989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Direct degradation and stabilization of proteins: New horizons in treatment of nonalcoholic steatohepatitis"],"prefix":"10.1016","volume":"220","author":[{"given":"Yibing","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2023.115989_b0005","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis","volume":"20","author":"Le","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0010","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/hep.32228","article-title":"Global burden of NAFLD and chronic liver disease among adolescents and young adults","volume":"75","author":"Paik","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115989_b0015","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0020","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2023.115989_b0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0030","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115989_b0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","article-title":"The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer","volume":"12","author":"Affo","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.bcp.2023.115989_b0040","first-page":"1175","volume":"323","author":"Sheka","year":"2020","journal-title":"Nonalcoholic Steatohepatitis: A Review. Jama"},{"key":"10.1016\/j.bcp.2023.115989_b0045","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1111\/liv.15024","article-title":"Diet and exercise in NAFLD\/NASH: Beyond the obvious","volume":"41","author":"Semmler","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.bcp.2023.115989_b0050","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0055","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41574-022-00711-5","article-title":"Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation","volume":"18","author":"Lonardo","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.bcp.2023.115989_b0060","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2023.115989_b0065","volume":"12","author":"Smits","year":"2021","journal-title":"Safety of Semaglutide. Front Endocrinol (lausanne)"},{"key":"10.1016\/j.bcp.2023.115989_b0070","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2023.115989_b0075","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2023.115989_b0080","article-title":"Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach","volume":"1\u201310","author":"Brennan","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0085","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2023.115989_b0090","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1021\/acs.jmedchem.9b01701","article-title":"The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease","volume":"63","author":"Romero","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2023.115989_b0095","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0100","first-page":"S46","article-title":"Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status","volume":"12","author":"Roy","year":"2022","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"10.1016\/j.bcp.2023.115989_b0105","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2023.115989_b0110","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/acsptsci.1c00041","article-title":"Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR\/sEH Modulation in NASH in Diet-Induced Obese Mice","volume":"4","author":"Helmst\u00e4dter","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.bcp.2023.115989_b0115","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/gutjnl-2021-326874","article-title":"Current therapies and new developments in NASH","volume":"71","author":"Dufour","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2023.115989_b0120","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2023.115989_b0125","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2023.115989_b0130","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2023.115989_b0135","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115989_b0140","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2023.115989_b0145","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","article-title":"Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study","volume":"78","author":"Anstee","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115989_b0150","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/hepr.13695","article-title":"Efficacy and safety of apararenone (MT-3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study","volume":"51","author":"Okanoue","year":"2021","journal-title":"Hepatol Res"},{"key":"10.1016\/j.bcp.2023.115989_b0155","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115989_b0160","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0165","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jhep.2020.03.024","article-title":"Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study","volume":"73","author":"Newsome","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2023.115989_b0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0180","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0185","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.3748\/wjg.v28.i35.5129","article-title":"Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis","volume":"28","author":"Suri","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bcp.2023.115989_b0190","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1021\/acs.jmedchem.0c00339","article-title":"Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase","volume":"63","author":"Li","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2023.115989_b0195","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2023.115989_b0200","doi-asserted-by":"crossref","first-page":"e153724","DOI":"10.1172\/JCI153724","article-title":"Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice","volume":"132","author":"Bhat","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2023.115989_b0205","doi-asserted-by":"crossref","unstructured":"Faridoon, Ng, R., Zhang, G. & Li, J.J. An update on the discovery and development of reversible covalent inhibitors. Med Chem Res 32, 1039-1062 (2023).","DOI":"10.1007\/s00044-023-03065-3"},{"key":"10.1016\/j.bcp.2023.115989_b0210","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1039\/D2MD00216G","article-title":"Advanced approaches of developing targeted covalent drugs","volume":"13","author":"Gai","year":"2022","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.bcp.2023.115989_b0215","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.1039\/D2CS00478J","article-title":"PROTAC degraders as chemical probes for studying target biology and target validation","volume":"51","author":"N\u011bmec","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bcp.2023.115989_b0220","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.molcel.2020.04.023","article-title":"Using Chemical Epigenetics to Target Cancer","volume":"78","author":"Wimalasena","year":"2020","journal-title":"Mol Cell"},{"key":"10.1016\/j.bcp.2023.115989_b0225","doi-asserted-by":"crossref","unstructured":"15 years of Nature Chemical Biology. Nat Chem Biol 16, 597 (2020).","DOI":"10.1038\/s41589-020-0560-7"},{"key":"10.1016\/j.bcp.2023.115989_b0230","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1002\/hep.32061","article-title":"The E3 Ubiquitin Ligase Ring Finger Protein 5 Ameliorates NASH Through Ubiquitin-Mediated Degradation of 3-Hydroxy-3-Methylglutaryl CoA Reductase Degradation Protein 1","volume":"74","author":"Yang","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115989_b0235","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/hep.32179","article-title":"OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways","volume":"75","author":"Zhang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115989_b0240","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2023.115989_b0245","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41589-021-00878-4","article-title":"Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity","volume":"17","author":"Imaide","year":"2021","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bcp.2023.115989_b0250","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bcp.2023.115989_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115127","article-title":"Developments of PROTACs technology in immune-related diseases","volume":"249","author":"Wang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bcp.2023.115989_b0260","doi-asserted-by":"crossref","first-page":"16930","DOI":"10.1021\/jacs.2c05499","article-title":"Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2","volume":"144","author":"Liu","year":"2022","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bcp.2023.115989_b0265","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/acsmedchemlett.9b00385","article-title":"PROTAC Degradation of IRAK4 for the Treatment of Neurodegenerative and Cardiovascular Diseases","volume":"10","author":"Kargbo","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bcp.2023.115989_b0270","doi-asserted-by":"crossref","first-page":"11454","DOI":"10.1021\/acs.jmedchem.2c00844","article-title":"Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy","volume":"65","author":"Fang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2023.115989_b0275","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.1021\/acs.jmedchem.3c00822","article-title":"Discovery of NAFLD-Improving Agents by Promoting the Degradation of Keap1","volume":"66","author":"Qi","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2023.115989_b0280","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1080\/15548627.2020.1757955","article-title":"Discovery of a potent SCAP degrader that ameliorates HFD-induced obesity, hyperlipidemia and insulin resistance via an autophagy-independent lysosomal pathway","volume":"17","author":"Zheng","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.bcp.2023.115989_b0285","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bcp.2023.115989_b0290","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2023.115989_b0295","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature14557","article-title":"The CREB coactivator CRTC2 controls hepatic lipid metabolism by regulating SREBP1","volume":"524","author":"Han","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2023.115989_b0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba4448","article-title":"Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis","volume":"12","author":"Govaere","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bcp.2023.115989_b0305","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41588-022-01199-5","article-title":"Multiomics study of nonalcoholic fatty liver disease","volume":"54","author":"Sveinbjornsson","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.bcp.2023.115989_b0310","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0315","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1053\/j.gastro.2021.02.051","article-title":"Squalene Epoxidase Induces Nonalcoholic Steatohepatitis Via Binding to Carbonic Anhydrase III and is a Therapeutic Target","volume":"160","author":"Liu","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2023.115989_b0320","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jcmgh.2020.10.006","article-title":"S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis","volume":"11","author":"Zhang","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0325","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144801","article-title":"Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2023.115989_b0330","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2022.09.027","article-title":"Hepatocyte Adenosine Kinase Promotes Excessive Fat Deposition and Liver Inflammation","volume":"164","author":"Li","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2023.115989_b0335","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/hep.31995","article-title":"Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis","volume":"74","author":"Kozumi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115989_b0340","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/hep.32662","article-title":"Hepatocyte-derived MASP1-enriched small extracellular vesicles activate HSCs to promote liver fibrosis","volume":"77","author":"Liu","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115989_b0345","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2020.03.010","article-title":"Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis","volume":"31","author":"Wang","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.bcp.2023.115989_b0350","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/s41591-023-02553-8","article-title":"Interaction between estrogen receptor-\u03b1 and PNPLA3 p. I148M variant drives fatty liver disease susceptibility in women","volume":"29","author":"Cherubini","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2023.115989_b0355","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.scib.2023.04.028","article-title":"Stimuli-activatable PROTACs for precise protein degradation and cancer therapy","volume":"68","author":"Gao","year":"2023","journal-title":"Sci Bull (beijing)"},{"key":"10.1016\/j.bcp.2023.115989_b0360","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1038\/s41467-023-40327-5","article-title":"Cullin-associated and neddylation-dissociated protein 1 (CAND1) alleviates NAFLD by reducing ubiquitinated degradation of ACAA2","volume":"14","author":"Huang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.bcp.2023.115989_b0365","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1053\/j.gastro.2004.07.019","article-title":"Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses","volume":"127","author":"Takehara","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2023.115989_b0370","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/hep.32569","article-title":"Lipocalin-2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high-fat diet-fed Ob\/Ob mice","volume":"77","author":"Kim","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115989_b0375","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3390\/molecules27061977","article-title":"Development of an LC-MS\/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies","volume":"27","author":"Nguyen","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2023.115989_b0380","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2023.115989_b0385","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1021\/acs.jmedchem.0c01689","article-title":"Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery","volume":"64","author":"Pei","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2023.115989_b0390","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2021.11.009","article-title":"A new perspective on NAFLD: Focusing on lipid droplets","volume":"76","author":"Scorletti","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0395","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41467-022-28520-4","article-title":"The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system","volume":"13","author":"Ji","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.bcp.2023.115989_b0400","doi-asserted-by":"crossref","first-page":"16377","DOI":"10.1021\/jacs.1c08521","article-title":"Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation","volume":"143","author":"Zhang","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bcp.2023.115989_b0405","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1186\/s12864-017-4225-1","article-title":"Whole genome analysis of CRISPR Cas9 sgRNA off-target homologies via an efficient computational algorithm","volume":"18","author":"Zhou","year":"2017","journal-title":"BMC Genomics"},{"key":"10.1016\/j.bcp.2023.115989_b0410","doi-asserted-by":"crossref","first-page":"16497","DOI":"10.1021\/acs.jmedchem.1c00996","article-title":"Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells","volume":"64","author":"Cao","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2023.115989_b0415","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bcp.2023.115989_b0420","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bcp.2023.115989_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128636","article-title":"Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases","volume":"64","author":"Aublette","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bcp.2023.115989_b0430","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1751-2980.2011.00554.x","article-title":"Liver X receptors bridge hepatic lipid metabolism and inflammation","volume":"13","author":"Liu","year":"2012","journal-title":"J Dig Dis"},{"key":"10.1016\/j.bcp.2023.115989_b0435","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.immuni.2020.04.001","article-title":"Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis","volume":"52","author":"Seidman","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2023.115989_b0440","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molmet.2015.01.009","article-title":"The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis","volume":"4","author":"Griffett","year":"2015","journal-title":"Mol Metab"},{"key":"10.1016\/j.bcp.2023.115989_b0445","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.674967","article-title":"Development of Agonist-Based PROTACs Targeting Liver X Receptor","volume":"9","author":"Xu","year":"2021","journal-title":"Front Chem"},{"key":"10.1016\/j.bcp.2023.115989_b0450","doi-asserted-by":"crossref","first-page":"eadh0831","DOI":"10.1126\/sciadv.adh0831","article-title":"Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC","volume":"9","author":"Boslem","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.bcp.2023.115989_b0455","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1053\/j.gastro.2020.06.031","article-title":"IRE1A Stimulates Hepatocyte-Derived Extracellular Vesicles That Promote Inflammation in Mice With Steatohepatitis","volume":"159","author":"Dasgupta","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2023.115989_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115667","article-title":"Soluble epoxide hydrolase-targeting PROTAC activates AMPK and inhibits endoplasmic reticulum stress","volume":"168","author":"Peyman","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bcp.2023.115989_b0465","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jhep.2020.09.037","article-title":"Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis","volume":"74","author":"Mohs","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0470","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2023.115989_b0475","doi-asserted-by":"crossref","first-page":"e98896","DOI":"10.1371\/journal.pone.0098896","article-title":"Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO","volume":"9","author":"Cleasby","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2023.115989_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102783","article-title":"Development of KEAP1-targeting PROTAC and its antioxidant properties: In vitro and in vivo","volume":"64","author":"Park","year":"2023","journal-title":"Redox Biol"},{"key":"10.1016\/j.bcp.2023.115989_b0485","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.bcp.2023.115989_b0490","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2016.03.011","article-title":"PNPLA3 gene in liver diseases","volume":"65","author":"Tr\u00e9po","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0495","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","article-title":"Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice","volume":"22","author":"Lind\u00e9n","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.bcp.2023.115989_b0500","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1073\/pnas.1901974116","article-title":"Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis","volume":"116","author":"BasuRay","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bcp.2023.115989_b0505","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1038\/s41467-021-27539-3","article-title":"The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression","volume":"12","author":"Li","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bcp.2023.115989_b0510","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nchembio.2538","article-title":"Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation","volume":"14","author":"Olson","year":"2018","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bcp.2023.115989_b0515","doi-asserted-by":"crossref","first-page":"E589","DOI":"10.1152\/ajpendo.00338.2022","article-title":"Hepatic mTORC2 compensates for loss of adipose mTORC2 in mediating energy storage and glucose homeostasis","volume":"324","author":"Frei","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.bcp.2023.115989_b0520","article-title":"Post-Translational Regulation of HMG CoA Reductase","volume":"14","author":"Jo","year":"2022","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.bcp.2023.115989_b0525","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/aps.2016.158","article-title":"Dicer1\/miR-29\/HMGCR axis contributes to hepatic free cholesterol accumulation in mouse non-alcoholic steatohepatitis","volume":"38","author":"Liu","year":"2017","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bcp.2023.115989_b0530","doi-asserted-by":"crossref","first-page":"8229","DOI":"10.3390\/ijms23158229","article-title":"Unraveling the Transcriptional Dynamics of NASH Pathogenesis Affecting Atherosclerosis","volume":"23","author":"van den Hoek","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bcp.2023.115989_b0535","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep4.1801","article-title":"Role of Cholesterol-Associated Steatohepatitis in the Development of NASH","volume":"6","author":"Horn","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.bcp.2023.115989_b0540","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The Role of Cholesterol in the Pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.bcp.2023.115989_b0545","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41419-019-1322-x","article-title":"Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells","volume":"10","author":"G\u00f6bel","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bcp.2023.115989_b0550","doi-asserted-by":"crossref","first-page":"11687","DOI":"10.3390\/ijms222111687","article-title":"Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy","volume":"22","author":"Vinci","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bcp.2023.115989_b0555","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.apsb.2020.11.001","article-title":"Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo","volume":"11","author":"Luo","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bcp.2023.115989_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114323","article-title":"Synthesis of heterocyclic ring-fused analogs of HMG499 as novel degraders of HMG-CoA reductase that lower cholesterol","volume":"236","author":"Li","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bcp.2023.115989_b0565","doi-asserted-by":"crossref","first-page":"e137127","DOI":"10.1172\/jci.insight.137127","article-title":"Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice","volume":"5","author":"Sanders","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.bcp.2023.115989_b0570","doi-asserted-by":"crossref","first-page":"L1183","DOI":"10.1152\/ajplung.00224.2016","article-title":"BRD4 mediates NF-\u03baB-dependent epithelial-mesenchymal transition and pulmonary fibrosis via transcriptional elongation","volume":"311","author":"Tian","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.bcp.2023.115989_b0575","doi-asserted-by":"crossref","first-page":"15713","DOI":"10.1073\/pnas.1522163112","article-title":"BRD4 is a novel therapeutic target for liver fibrosis","volume":"112","author":"Ding","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bcp.2023.115989_b0580","article-title":"Hepatic BRD4 Is Upregulated in Liver Fibrosis of Various Etiologies and Positively Correlated to Fibrotic Severity","volume":"8","author":"Wu","year":"2021","journal-title":"Front Med (lausanne)"},{"key":"10.1016\/j.bcp.2023.115989_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113922","article-title":"Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET\/PLK1 inhibitor","volume":"227","author":"Hu","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bcp.2023.115989_b0590","doi-asserted-by":"crossref","first-page":"15073","DOI":"10.1021\/jacs.1c04841","article-title":"Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation","volume":"143","author":"Wei","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bcp.2023.115989_b0595","doi-asserted-by":"crossref","first-page":"D1381","DOI":"10.1093\/nar\/gkaa807","article-title":"PROTAC-DB: an online database of PROTACs","volume":"49","author":"Weng","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bcp.2023.115989_b0600","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.cell.2020.10.038","article-title":"Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development","volume":"183","author":"Donovan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2023.115989_b0605","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.cmet.2021.05.019","article-title":"Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1","volume":"33","author":"Wang","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.bcp.2023.115989_b0610","doi-asserted-by":"crossref","first-page":"e2792","DOI":"10.1038\/cddis.2017.10","article-title":"MiR-130a-3p attenuates activation and induces apoptosis of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis by directly targeting TGFBR1 and TGFBR2","volume":"8","author":"Wang","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bcp.2023.115989_b0615","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jhep.2020.09.033","article-title":"Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis","volume":"74","author":"Morikawa","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.bcp.2023.115989_b0620","doi-asserted-by":"crossref","first-page":"e202116782","DOI":"10.1002\/anie.202116782","article-title":"A Chemical Biology Toolbox Targeting the Intracellular Binding Site of CCR9: Fluorescent Ligands, New Drug Leads and PROTACs","volume":"61","author":"Huber","year":"2022","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.bcp.2023.115989_b0625","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/s41418-020-00668-w","article-title":"RIP1 kinase activity promotes steatohepatitis through mediating cell death and inflammation in macrophages","volume":"28","author":"Tao","year":"2021","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.bcp.2023.115989_b0630","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.molcel.2019.12.003","article-title":"Lipid Droplet-Derived Monounsaturated Fatty Acids Traffic via PLIN5 to Allosterically Activate SIRT1","volume":"77","author":"Najt","year":"2020","journal-title":"Mol Cell"},{"key":"10.1016\/j.bcp.2023.115989_b0635","doi-asserted-by":"crossref","first-page":"32443","DOI":"10.1073\/pnas.2011442117","article-title":"Direct lysosome-based autophagy of lipid droplets in hepatocytes","volume":"117","author":"Schulze","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bcp.2023.115989_b0640","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2023.115989_b0645","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41422-021-00532-7","article-title":"Degradation of lipid droplets by chimeric autophagy-tethering compounds","volume":"31","author":"Fu","year":"2021","journal-title":"Cell Res"},{"key":"10.1016\/j.bcp.2023.115989_b0650","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1080\/15548627.2023.2220540","article-title":"Clearance of lipid droplets by chimeric autophagy-tethering compound ameliorates the age-related macular degeneration phenotype in mice lacking APOE","volume":"19","author":"Zhang","year":"2023","journal-title":"Autophagy"},{"key":"10.1016\/j.bcp.2023.115989_b0655","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1080\/15548627.2023.2234797","article-title":"Tethering ATG16L1 or LC3 induces targeted autophagic degradation of protein aggregates and mitochondria","volume":"19","author":"Mei","year":"2023","journal-title":"Autophagy"},{"key":"10.1016\/j.bcp.2023.115989_b0660","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/hep.29742","article-title":"Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62\/sequestosome 1 phosphorylation","volume":"68","author":"Cho","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115989_b0665","article-title":"Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice","volume":"5","author":"Seedorf","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.bcp.2023.115989_b0670","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.26207","article-title":"Brahma-related gene 1 bridges epigenetic regulation of proinflammatory cytokine production to steatohepatitis in mice","volume":"58","author":"Tian","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115989_b0675","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2023.115989_b0680","article-title":"Light-Controllable PROTACs for Temporospatial Control of Protein Degradation","volume":"9","author":"Liu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.bcp.2023.115989_b0685","doi-asserted-by":"crossref","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","article-title":"Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity","volume":"66","author":"Chen","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2023.115989_b0690","doi-asserted-by":"crossref","first-page":"14155","DOI":"10.1021\/jacs.3c05159","article-title":"Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation","volume":"145","author":"Chang","year":"2023","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bcp.2023.115989_b0695","doi-asserted-by":"crossref","first-page":"12978","DOI":"10.1021\/acs.jmedchem.1c01118","article-title":"Optimization of a Series of RIPK2 PROTACs","volume":"64","author":"Miah","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2023.115989_b0700","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1038\/s41467-022-33430-6","article-title":"A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo","volume":"13","author":"Kofink","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.bcp.2023.115989_b0705","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1021\/acs.jmedchem.3c00740","article-title":"Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders","volume":"66","author":"Hornberger","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2023.115989_b0710","doi-asserted-by":"crossref","unstructured":"Ermondi, G., Jimenez, D.G., Rossi Sebastiano, M., Kihlberg, J. & Caron, G. Conformational Sampling Deciphers the Chameleonic Properties of a VHL-Based Degrader. Pharmaceutics 15(2023).","DOI":"10.3390\/pharmaceutics15010272"},{"key":"10.1016\/j.bcp.2023.115989_b0715","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41419-018-0514-0","article-title":"ZBTB20 regulates EGFR expression and hepatocyte proliferation in mouse liver regeneration","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bcp.2023.115989_b0720","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1002\/hep.32075","article-title":"SIMPLE Is an Endosomal Regulator That Protects Against NAFLD by Targeting the Lysosomal Degradation of EGFR","volume":"74","author":"Song","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115989_b0725","doi-asserted-by":"crossref","first-page":"849","DOI":"10.17219\/acem\/68846","article-title":"CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration","volume":"27","author":"Koper","year":"2018","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.bcp.2023.115989_b0730","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.7150\/thno.21400","article-title":"Pro-Inflammatory CXCR3 Impairs Mitochondrial Function in Experimental Non-Alcoholic Steatohepatitis","volume":"7","author":"Du","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2023.115989_b0735","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/cmdc.202100393","article-title":"LYTACs: An Emerging Tool for the Degradation of Non-Cytosolic Proteins","volume":"16","author":"Ramadas","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2023.115989_b0740","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2023.115989_b0745","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bcp.2023.115989_b0750","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2023.115989_b0755","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/endrev\/bnab035","article-title":"The Multifaceted Biology of PCSK9","volume":"43","author":"Seidah","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bcp.2023.115989_b0760","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/17512433.2022.2132229","article-title":"The role of PCSK9 in NAFLD\/NASH and therapeutic implications of PCSK9 inhibition","volume":"15","author":"Momtazi-Borojeni","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.bcp.2023.115989_b0765","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1021\/acschembio.3c00229","article-title":"Synthetic Site-Specific Antibody-Ligand Conjugates Promote Asialoglycoprotein Receptor-Mediated Degradation of Extracellular Human PCSK9","volume":"18","author":"Donahue","year":"2023","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bcp.2023.115989_b0770","doi-asserted-by":"crossref","first-page":"eabe1692","DOI":"10.1126\/scitranslmed.abe1692","article-title":"Hepatocyte TLR4 triggers inter-hepatocyte Jagged1\/Notch signaling to determine NASH-induced fibrosis","volume":"13","author":"Yu","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bcp.2023.115989_b0775","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s42255-020-0261-2","article-title":"Fructose stimulated de novo lipogenesis is promoted by inflammation","volume":"2","author":"Todoric","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.bcp.2023.115989_b0780","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/nm.4334","article-title":"Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4","volume":"23","author":"Zhao","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2023.115989_b0785","doi-asserted-by":"crossref","first-page":"5708692","DOI":"10.1155\/2020\/5708692","article-title":"Monoclonal Antibody to CD14, TLR4, or CD11b: Impact of Epitope and Isotype Specificity on ROS Generation by Human Granulocytes and Monocytes","volume":"2020","author":"Kabanov","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.bcp.2023.115989_b0790","doi-asserted-by":"crossref","first-page":"e10124","DOI":"10.15252\/emmm.201810124","article-title":"Liver ASK1 protects from non-alcoholic fatty liver disease and fibrosis","volume":"11","author":"Challa","year":"2019","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.bcp.2023.115989_b0795","doi-asserted-by":"crossref","first-page":"11816","DOI":"10.1096\/fj.202000678R","article-title":"Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD","volume":"34","author":"Weber","year":"2020","journal-title":"Faseb j"},{"key":"10.1016\/j.bcp.2023.115989_b0800","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.bcp.2023.115989_b0805","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41589-022-00971-2","article-title":"Deubiquitinase-targeting chimeras for targeted protein stabilization","volume":"18","author":"Henning","year":"2022","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bcp.2023.115989_b0810","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00018-023-04755-2","article-title":"The forkhead box O3 (FOXO3): a key player in the regulation of ischemia and reperfusion injury","volume":"80","author":"Omorou","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bcp.2023.115989_b0815","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3390\/antiox11050799","article-title":"Empagliflozin-Enhanced Antioxidant Defense Attenuates Lipotoxicity and Protects Hepatocytes by Promoting FoxO3a- and Nrf2-Mediated Nuclear Translocation via the CAMKK2\/AMPK Pathway","volume":"11","author":"Wang","year":"2022","journal-title":"Antioxidants (basel)"},{"key":"10.1016\/j.bcp.2023.115989_b0820","doi-asserted-by":"crossref","first-page":"12934","DOI":"10.1021\/jacs.2c04824","article-title":"TF-DUBTACs Stabilize Tumor Suppressor Transcription Factors","volume":"144","author":"Liu","year":"2022","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bcp.2023.115989_b0825","doi-asserted-by":"crossref","first-page":"5990156","DOI":"10.1155\/2023\/5990156","article-title":"c-Myb Dominates TBK1-Mediated Endotoxin Tolerance in Kupffer Cells by Negatively Regulating DTX4","volume":"2023","author":"Wu","year":"2023","journal-title":"J Immunol Res"},{"key":"10.1016\/j.bcp.2023.115989_b0830","article-title":"TRIM26 Induces Ferroptosis to Inhibit Hepatic Stellate Cell Activation and Mitigate Liver Fibrosis Through Mediating SLC7A11 Ubiquitination","volume":"9","author":"Zhu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.bcp.2023.115989_b0835","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41419-021-03493-2","article-title":"Hypothermic oxygenated perfusion inhibits HECTD3-mediated TRAF3 polyubiquitination to alleviate DCD liver ischemia-reperfusion injury","volume":"12","author":"Zhou","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bcp.2023.115989_b0840","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41467-022-28641-w","article-title":"The E3 ubiquitin-protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rhbdf2 in mouse hepatocytes","volume":"13","author":"Xu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.bcp.2023.115989_b0845","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.872729","article-title":"Overcoming Cancer Drug Resistance Utilizing PROTAC Technology","volume":"10","author":"Burke","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.bcp.2023.115989_b0850","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1124\/dmd.123.001449","article-title":"Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5\/ACLY Signaling Axis","volume":"51","author":"Sun","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2023.115989_b0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100123","article-title":"Inhibition of chylomicron assembly leads to dissociation of hepatic steatosis from inflammation and fibrosis","volume":"62","author":"Xie","year":"2021","journal-title":"J Lipid Res"},{"key":"10.1016\/j.bcp.2023.115989_b0860","doi-asserted-by":"crossref","first-page":"e202217246","DOI":"10.1002\/anie.202217246","article-title":"Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation","volume":"62","author":"Xie","year":"2023","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.bcp.2023.115989_b0865","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jhepr.2019.10.009","article-title":"Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice","volume":"1","author":"Lebeau","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.bcp.2023.115989_b0870","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/164_2019_232","article-title":"Nonsteroidal FXR Ligands: Current Status and Clinical Applications","volume":"256","author":"Gege","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.bcp.2023.115989_b0875","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.bcp.2023.115989_b0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100051","article-title":"ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score","volume":"2","author":"Sanjay","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.bcp.2023.115989_b0885","article-title":"Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice","volume":"4","author":"Desjardins","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.bcp.2023.115989_b0890","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41467-019-14138-6","article-title":"SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bcp.2023.115989_b0895","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1136\/gutjnl-2021-324834","article-title":"Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model","volume":"71","author":"Kumar","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2023.115989_b0900","doi-asserted-by":"crossref","first-page":"eaba7791","DOI":"10.1126\/scitranslmed.aba7791","article-title":"A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models","volume":"13","author":"Lightcap","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bcp.2023.115989_b0905","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood.2021014267","article-title":"The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation","volume":"139","author":"Nakamura","year":"2022","journal-title":"Blood"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223005828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223005828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:17:58Z","timestamp":1762096678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223005828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":181,"alternative-id":["S0006295223005828"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115989","relation":{},"ISSN":["0006-2952"],"issn-type":[{"type":"print","value":"0006-2952"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct degradation and stabilization of proteins: New horizons in treatment of nonalcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115989"}}